MedTrace Logo

Pilot Study of Fosamax in Spinal Cord Injury

NCT01131884 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2016-01-29

Study results available
· View outcomes & findings →

Summary

Study is designed to evaluate the efficacy of oral fosamax in prevention on osteoporosis in acute spinal cord injury. Efficacy will be measured by a duel energy X-Ray absorptiometry (DEXA) scan every 6 months. Patients will complete 3 visits, screening, 6 months, 12 months and be required to take oral fosamax versus placebo weekly.

Conditions

Interventions

DRUG

Fosamax

70mg of Bisphosphonate therapy (Fosamax) will be taken weekly for a year

DRUG

Placebo

Placebo is an inactive pill that will look similar to the active drug. You will not know whether you are receiving active drug or placebo.

Sponsors & Collaborators

  • University of Rochester

    lead OTHER

Principal Investigators

  • Kanakadurga R Poduri, M.D. · University of Rochester

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01131884 on ClinicalTrials.gov